The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Sep 30, 2026
RTW Biotech Opportunities Ltd recorded a NAV per share return of -5.6% net of fees in the third quarter of 2026, outperforming the Russell 2000 Biotech Index (-2.8%) while trailing the Nasdaq Biotech Index (+8.5%). Year-to-date net NAV return reached +10.0%, with ordinary share price returns standing at +10.2% net of fees. At quarter-end, the fund's gross economic sub-portfolio exposures stood at 89.1% in public equities, 19.8% in private holdings, and 2.0% in royalties. The share price discount to NAV narrowed substantially from 27.5% to 11.8% over the trailing twelve months, aided by disciplined capital allocation and $13.4 million in share buybacks. Macroeconomic cross-currents featured the Federal Reserve raising interest rates by 25 basis points in September, pushing 10-year Treasury yields above 5%. RTW anticipates interest rate shifts will exert less pressure on biotechnology valuations than in prior cycles, noting the sector's positive correlation (+0.84) to Treasury yields and growing reliance on idiosyncratic clinical catalysts and earnings. Concurrently, pharmaceutical M&A is tracking toward its strongest year since 2019, driven by an acute patent expiry wave and large-cap pharma pipeline setbacks. Capital markets remained active with 22 year-to-date IPOs, alongside stabilized FDA regulatory leadership. Portfolio activity was marked by significant clinical readouts and targeted capital deployment. Ultragenyx and uniQure detracted from performance following clinical trial setbacks in Angelman Syndrome and Huntington's disease, respectively. Offsetting these headwinds, top contributors included UroGen, Oruka, and Spyre. RTW deployed an additional $4.1 million into private portfolio company Encoded Therapeutics as part of its $275 million Series F round, while maintaining top core holdings across oncology, immunology, and rare disease commercial leaders.
RTW Biotech Opportunities identifies transformative assets across the full public and private life sciences cycle, capitalizing on deep scientific rigor, the biopharma patent expiry wave, and corporate M&A demand.
Interest rate tightening is expected to have less influence on biotechnology than during prior cycles, with M&A, clinical readouts, and commercial earnings remaining primary performance drivers.
Moderate Conviction Bullish
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with RTW Investments or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.